Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Select Drug Profiles
FDA Approvals
,
Select Drug Profiles
FDA Approves First Prostate-Specific Membrane Antigen–Targeted PET Imaging Drug for Prostate Cancer
Read More
FDA Approvals
,
Leukemia
,
Select Drug Profiles
Oral Onureg First Drug Approved for Adults with AML in Remission
Read More
FDA Approvals
,
Select Drug Profiles
Danyelza Receives FDA Approval for High-Risk Neuroblastoma in the Bone and Bone Marrow
Read More
FDA Approvals
,
Select Drug Profiles
Gavreto, a New RET Inhibitor, Now Approved for Thyroid Cancer with RET Fusions
Read More
FDA Approvals
,
Select Drug Profiles
Opdivo Approved for Advanced Esophageal Squamous-Cell Carcinoma
Read More
FDA Approvals
,
Lung Cancer
,
Select Drug Profiles
FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation
Read More
FDA Approvals
,
Lung Cancer
,
Select Drug Profiles
Opdivo plus Yervoy and Limited Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression
Read More
FDA Approvals
,
Lung Cancer
,
Select Drug Profiles
Tecentriq plus Avastin First Immunotherapy Regimen Approved for Metastatic Hepatocellular Carcinoma
Read More
FDA Approvals
,
Prostate Cancer
,
Select Drug Profiles
Lynparza First Targeted Therapy Approved for Metastatic Prostate Cancer with HRR Mutation
Read More
FDA Approvals
,
Lung Cancer
,
Select Drug Profiles
Tecentriq Approved as First-Line Therapy for Metastatic NSCLC with High PD-L1 Expression
Read More
1
2
3
4
5
6
Page 3 of 20
Results 21 - 30 of 200